H1N1 Antibody Persistence 1 Year After Immunization With an Adjuvanted or Whole-Virion Pandemic Vaccine and Immunogenicity and Reactogenicity of Subsequent Seasonal Influenza Vaccine: A Multicenter Follow-on Study

• Published in: Clinical infectious diseases 2012-03, Vol.54 (5), p.661-669
• Main Authors: Walker, Woolf T., de Whalley, Philip, Andrews, Nick, Oeser, Clarissa, Casey, Michelle, Michaelis, Louise, Hoschler, Katja, Harrill, Caroline, Moulsdale, Phoebe, Thompson, Ben, Jones, Claire, Chalk, Jem, Kerridge, Simon, John, Tessa M., Okike, Ifeanyichukwu, Ladhani, Shamez, Tomlinson, Richard, Heath, Paul T., Miller, Elizabeth, Faust, Saul N., Snape, Matthew D., Finn, Adam, Pollard, Andrew J.
• Format: Article
• Language: English
• Subjects: Adjuvants, Immunologic; Age; Age groups; and Commentaries; Antibodies; Antibodies, Viral - blood; Antibodies, Viral - immunology; ARTICLES AND COMMENTARIES; Biological and medical sciences; Children; Children & youth; Dosage; Follow-Up Studies; H1N1 subtype influenza A virus; Hemagglutination Inhibition Tests; Human viral diseases; Humans; Immune response; Immunization; Immunogenicity; Immunoglobulins; Infections; Infectious diseases; Influenza; Influenza A Virus, H1N1 Subtype - immunology; Influenza vaccines; Influenza Vaccines - administration & dosage; Influenza Vaccines - adverse effects; Influenza Vaccines - immunology; Influenza, Human - immunology; Influenza, Human - prevention & control; Medical sciences; Neutralization Tests; Pandemics; Seasonal variations; Sulfur dioxide; Swine flu; Vaccination; Vaccines; Viral diseases; Viral diseases of the respiratory system and ent viral diseases; Virion - immunology
• ISSN: 1058-4838; 1537-6591
• DOI: 10.1093/cid/cir905

Background. We investigated antibody persistence in children 1 year after 2 doses of either an AS03 B -adjuvanted split-virion or nonadjuvanted whole-virion monovalent pandemic influenza vaccine and assessed the immunogenicity and reactogenicity of a subsequent dose of trivalent influenza vaccine (TIV). Methods. Children previously immunized at age 6 months to 12 years in the original study were invited to participate. After a blood sample was obtained to assess persistence of antibody against swine influenza A/H1N1(2009) pandemic influenza, children received 1 dose of 2010/2011 TIV, reactogenicity data were collected for 7 days, and another blood sample was obtained 21 days after vaccination. Results. Of 323 children recruited, 302 received TIV. Antibody persistence (defined as microneutralization [MN] titer ≥1:40) 1 year after initial vaccination was significantly higher in the AS03 B -adjuvanted compared with the whole-virion vaccine group, 100% (95% confidence interval [CI], 94.1%—100%) vs 32.4% (95% CI, 21.5%—44.8%) in children immunized